Pomalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 1 and 2 trial-Reference-Cited by-同舟云学术

Pomalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 1 and 2 trial

Published:2016-08-25 Issue:8 Volume:128 Page:1059-1062
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Sanchorawala Vaishali¹²^ORCID,Shelton Anthony C.¹²,Lo Stephen¹²,Varga Cindy¹²,Sloan J. Mark¹²^ORCID,Seldin David C.¹²

Affiliation:

1. Section of Hematology and Oncology, Department of Medicine, and

2. Amyloidosis Center, Boston University School of Medicine and Boston Medical Center, Boston, MA

Abstract

Key Points Pomalidomide is well tolerated in patients with AL amyloidosis; MTD of 4 mg/day on days 1 to 21 every 28 days. Pomalidomide and dexamethasone can lead to HR of 50% in previously treated patients with AL amyloidosis.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/128/8/1059/1465587/1059.pdf

Reference14 articles.

1. Tolerability and efficacy of thalidomide for the treatment of patients with light chain-associated (AL) amyloidosis.;Seldin;Clin Lymphoma,2003

2. A matched comparison of cyclophosphamide, bortezomib and dexamethasone (CVD) versus risk-adapted cyclophosphamide, thalidomide and dexamethasone (CTD) in AL amyloidosis.;Venner;Leukemia,2014

3. Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial.;Sanchorawala;Blood,2007

4. Poor tolerance to high doses of thalidomide in patients with primary systemic amyloidosis.;Dispenzieri;Amyloid,2003

5. The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis.;Dispenzieri;Blood,2007

Cited by 78 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cardiac Toxicity in the Treatment of Light Chain Amyloidosis: Systematic Review of Clinical Studies;Current Drug Safety;2024-11

2. Options for Rescue Treatment of Patients with AL Amyloidosis Exposed to Upfront Daratumumab;Current Oncology Reports;2024-06-19

3. High-dose melphalan-autologous hematopoietic cell transplantation in systemic AL amyloidosis following daratumumab-based frontline therapy;Bone Marrow Transplantation;2024-05-09

4. AL amyloidosis: an overview on diagnosis, staging system, and treatment;Frontiers in Hematology;2024-05-08

5. Immunoglobulin light chain amyloidosis: 2024 update on diagnosis, prognosis, and treatment;American Journal of Hematology;2023-12-14